SCHEMBL1574414

SCHEMBL1574414

CCOC(=O)c1cccc(NC(=O)N2CC(N3CCN(c4ccc(OC(F)(F)F)cc4)CC3)C2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.55
LMNA P02545 3/20 0.55
POLB P06746 2/20 0.49
ALDH1A1 P00352 1/20 0.49
MAPK1 P28482 1/20 0.49
HPGD P15428 2/20 0.46
KDM4E B2RXH2 1/20 0.46
TSHR P16473 1/20 0.45
SCN9A Q15858 1/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
LIPE Q05469 2/20 0.44
NPY2R P49146 1/20 0.44
P2RY12 Q9H244 3/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1574938 0.90 POLB (0.56) MAPTPOLBALDH1A1MAPK1KDM4E
SCHEMBL1574951 0.86 LMNA (0.65) MAPTLMNAPOLBALDH1A1MAPK1
SCHEMBL1574765 0.85 LMNA (0.59) MAPTLMNAPOLBALDH1A1MAPK1
SCHEMBL1574555 0.85 MAPT (0.54) MAPTLMNAPOLBMAPK1TSHR
SCHEMBL1574532 0.84 MAPT (0.50) MAPTLMNAPOLBALDH1A1MAPK1
SCHEMBL1574999 0.84 EPHX2 (0.53) MAPTLMNALIPECYP2C9CYP2C19
SCHEMBL1574622 0.83 EPHX2 (0.49) MAPTLMNAPOLBMAPK1KDM4E
SCHEMBL1574856 0.82 LMNA (0.48) MAPTLMNAPOLBMAPK1KDM4E
SCHEMBL1574496 0.82 LMNA (0.48) MAPTLMNAALDH1A1MAPK1TSHR
SCHEMBL1575145 0.80 POLB (0.51) MAPTLMNAPOLBLIPECYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB MAPT 3908/4885LMNA 1076/4885POLB 4641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.